Insider Buying: Vivani Medical (NASDAQ:VANI) Director Acquires $1,999,999.26 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired 1,587,301 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were bought at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the acquisition, the director directly owned 36,119,086 shares of the company’s stock, valued at approximately $45,510,048.36. This trade represents a 4.60% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Gregg Williams also recently made the following trade(s):

• On Friday, May 15th, Gregg Williams bought 1,587,301 shares of Vivani Medical stock. The shares were purchased at an average cost of $1.26 per share, for a total transaction of $1,999,999.26.
• On Wednesday, April 15th, Gregg Williams bought 1,587,301 shares of Vivani Medical stock. The stock was acquired at an average price of $1.26 per share, for a total transaction of $1,999,999.26.

Vivani Medical Price Performance

VANI stock opened at $1.15 on Friday. The firm has a market cap of $99.18 million, a PE ratio of -2.87 and a beta of 2.31. The business has a 50 day moving average of $1.22 and a 200-day moving average of $1.25. Vivani Medical, Inc. has a 12-month low of $0.92 and a 12-month high of $1.92.

Vivani Medical (NASDAQ:VANI) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). On average, research analysts expect that Vivani Medical, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a report on Tuesday, June 9th. HC Wainwright decreased their price objective on shares of Vivani Medical from $4.00 to $3.50 and set a “buy” rating for the company in a report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Vivani Medical currently has a consensus rating of “Hold” and a consensus target price of $3.50.

Hedge Funds Weigh In On Vivani Medical

Institutional investors have recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in Vivani Medical in the fourth quarter worth $1,127,000. Marshall Wace LLP purchased a new position in shares of Vivani Medical during the 4th quarter valued at $174,000. State Street Corp lifted its position in shares of Vivani Medical by 12.5% during the 4th quarter. State Street Corp now owns 144,865 shares of the company’s stock valued at $178,000 after buying an additional 16,070 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Vivani Medical during the 4th quarter worth $60,000. Finally, Renaissance Technologies LLC grew its stake in shares of Vivani Medical by 118.4% during the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after acquiring an additional 53,127 shares during the period. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.